He has served on the scientific advisory boards at BioSafe SA, Biolife Solutions, Inc., and General Electric and on the board of directors for the American Association of Blood Banks, or AABB, and the National Marrow Donor Program, or NMDP, which operates the “Be the Match” donor program.Ms Meldrum joined Mesoblast in 2004. Dr Grossman has led and built teams in the United States, Europe and Japan with responsibility for global medical affairs, global clinical development, health economics & outcomes research (HEOR) and global drug safety. Ms Meldrum is senior advisor to the Washington DC-based Alliance for Regenerative Medicine’s Communications and Education Committee. In 2011, he was named BioSpectrum Asia Person of the Year.
He has over 20 years of regulatory, clinical, product development, quality and reimbursement experience dealing with a variety of technologies from physiological monitoring equipment to implantable and biological products. 55 Collins Street
He received a Bachelor of Arts from Missouri’s William Jewell College and completed coursework at Oxford University in England.Mr Howard has been integrally involved with Mesoblast since its inception in 2004, when he played a critical role in the corporate structuring and listing of Mesoblast on the ASX. Mr Brown has also held clinical and regulatory roles at Axiomed Spine Corporation, Wright Medical Technology, CryoLife and Nellcor Puritan Bennett. She joined Mesoblast in December 2015.Eric Strati has over 17 years of experience across a broad range of industries within the healthcare sector including pharmaceutical, biotechnology, investment banking, and pharmacy benefit management. Prior to this, Ms Storton held executive roles at Hospira, and its predecessor companies in both regulatory affairs and quality, with a focus on major program management. Prior to joining Mesoblast in 2015, Dr Strati held various commercial leadership roles including new product planning, lifecycle management, sales, marketing, and payer strategy. Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.Mesoblast Limited provides biomedical services. Mr Muntner has a BFA from Carnegie Mellon and a MBA from the Anderson School at UCLA.Dr Grossman has over 20 years of industry experience, and has held key leadership positions at major global pharmaceutical companies, including Eli Lilly, Johnson & Johnson (J&J), Bristol Myers Squibb (BMS), Sunovion, and Glenmark.
She has been the recipient of the League of American Communication Professionals Gold Magellan Award, the United Nations Media Peace Prize for Radio, was a Governor of the Foreign Correspondents’ Club in Hong Kong and a Director of Australian Doctors International.
Dr Silviu Itescu, chief executive of stem-cell company Mesoblast. Ms Meldrum also served as a senior diplomat for 14 years promoting Australian policies and industries in the key markets of Japan, Hong Kong and Indonesia and has advised Prime Ministers, Cabinet Ministers and business leaders. Mr Howard has done so in several roles, including as a partner at a major law firm, entrepreneur, director and senior executive. As Head of Clinical Development, Medical Affairs & Drug Safety at 6,000-person global pharma Sunovion, a subsidiary of Japan’s Sumitomo Dainippon Pharma Co., Dr Grossman had responsibility across teams in the United States, Europe and Japan and successfully launched a blockbuster product in the United States market.
As Regional Director, Commercial Quality ANZ, Asia and Japan, Ms Storton was responsible for quality oversight and management of all products sold in Asia Pacific countries. Previous roles include non-executive Director of Diageo plc and Qinetiq plc., Chairman of the 100 Group of Finance Directors, Joint Chairman of the Business Tax Forum, board member of the Accounting Standards Board, and founder of the Oxford University Centre for Business Taxation Research, all in the United Kingdom.
Dr McMannis has 27 years of experience in clinical cellular therapy trials in both academic and commercial environments. During his career, he has managed global clinical development, pharmacovigilance, medical affairs and clinical operations for innovative product development, as well as United States Food and Drug Administration (FDA) approvals and post-market support for numerous blockbuster, specialty and generic products. Silviu Itescu is CEO/Managing Director at Mesoblast Ltd. See Silviu Itescu's compensation, career history, education, & memberships. Prior to working in the biopharmaceutical industry, she held faculty appointments at Columbia University's College of Physicians and Surgeons, Mount Sinai School of Medicine, and Weill Cornell Medical College conducting United States National Institutes of Health-funded research in diabetes, metabolism and obesity and directing the exercise physiology service in pediatric cardiology. Most recently, he led corporate development and financial transactions at Nasdaq-listed biotechnology company, ContraFect Corporation.